High Court’s Vaccines Ruling Gives Drug Makers Hope For Design Defect Claim Pre-emption
Executive Summary
The U.S. Supreme Court’s ruling that vaccine design defect claims are statutorily pre-empted could provide a potential defense in certain pharmaceutical product liability lawsuits, industry attorneys said.
You may also be interested in...
Supreme Court Immunizes Vaccine Manufacturers Against Design Defect Claims
In a 6-2 decision, the high court rules that manufacturers need not show that it would have been impossible to make a safer product and that plaintiffs' injuries were, therefore, unavoidable.
Supreme Court To Hear Generic Drug Preemption Cases Against Advice Of Solicitor General
The court agreed to review three cases in which generic manufacturers of Reglan (metoclopramide) were held responsible for warning about the risk of tardive dyskinesia.
Vaccine Liability: Supreme Court Justices Question Manufacturer “Motivation,” Comparative Safety
If the pharmaceutical industry is expecting a Supreme Court decision declaring blanket federal preemption of vaccine-related design defect claims, it must hope that questions raised by Supreme Court Justice Sonia Sotomayor in a vaccine liability case do not portend the views of the court’s majority.